Waldenstrom’s macroglobulinemia (WM) is a cancer of white blood cells called B lymphocytes. The purpose of this study is to find the highest dose of an investigational drug called IMO-8400 that can be given safely in patients with WM that has continued to grow or has come back despite prior therapy, and to observe the preliminary effectiveness of this drug in these patients.
IMO-8400 works by targeting proteins called Toll-like receptor 7 (TLR7), TLR8, and TLR9, which appear to be overactive in most patients with WM. Laboratory studies of WM showed that IMO-8400 resulted in tumor cell death. The drug is given as a subcutaneous (under the skin) injection.